CSF biomarkers in neurodegenerative parkinsonism can distinguish between multiple system atrophy and 4-repeat tauopathies, but not between disease with Lewy bodies and multiple system atrophy
Objective: To assess the usefulness of a defined set of blood-based and cerebrospinal fluid-based biomarkers in the differential diagnosis of neurodegenerative proteinopathies. Background: The diagnostic…Complications in Patients with Progressive Supranuclear Palsy
Objective: This study elucidated the incidence and features of complications in patients with progressive supranuclear palsy (PSP). Background: PSP is a progressive neurodegenerative disorder accompanied…Pan India Registry for Progressive Supranuclear Palsy (PAIR-PSP)
Objective: To understand Progressive Supranuclear palsy (PSP) phenotype and genotype from India. Background: Insights into PSP pathophysiology and newer clinical phenotypes are increasingly being recognized.…Plasma p-tau181 is increased in Lewy body dementia and relates to cognitive performance
Objective: To compare plasma p-tau181 concentration in Parkinson’s disease (PD), Lewy body dementia (LBD) and healthy controls and to examine the relationship between ptau-181 concentration…In-vivo measurement of tau depositions in anti-IgLON5 disease with 18F-PI2620-PET
Objective: The aim of the study was to examine the potential of the second-generation tau-PET tracer 18F-PI2620 to detect tau deposition in anti-IgLON5 disease. Background:…Novel Cognitive Markers for Early Diagnosis and Monitoring of Progressive Supranuclear Palsy
Objective: The aim of this study was to evaluate whether a novel computerised test could offer an inexpensive and reliable tool that can aid diagnosis…Benign Progressive Supranuclear Palsy: mild pathology associated with parkinsonism
Objective: Objective: To describe the clinical presentation and neuropathology of cases where the degree of tau pathology is mild, and the neuronal loss is anatomically…An evaluation of the application of clinical research criteria for corticobasal degeneration in a large clinico-pathological series
Objective: To evaluate diagnostic criteria for corticobasal degeneration (CBD) in relation to pathology and disease course. Background: The overlapping features of CBD and related conditions…Plasma microRNA expression profiling in patients with progressive supranuclear palsy. A five-microRNA panel in plasma was identified as a potential biomarker for progressive supranuclear palsy
Objective: Our objective was to identify differentially expressed, circulating miRNAs in PSP which could serve as diagnostic biomarker for this disease. Background: Progressive supranuclear palsy…Lateralized Tau Pathology in a Case of Lewy Body Dementia with Corticobasal Syndrome
Objective: To measure bilateral in vivo and postmortem tau pathology in a well-characterized patient presenting with corticobasal syndrome (CBS) due to underlying neocortical stage Lewy…
- « Previous Page
- 1
- …
- 3
- 4
- 5
- 6
- 7
- …
- 13
- Next Page »